Relmada Therapeutics

United States
Troy, New Hampshire, United States, 10022

Company profile

Relmada Therapeutics company profile

Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Our experienced and dedicated team is committed to making a difference in the lives of patients and their families. Relmada' s lead program, REL-1017, is a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 has entered late-stage development as an adjunctive treatment for MDD in adults.()

Business identity

Contact email
[email protected]
Phone number
646-876-3459
Operating status
Active
Company type
For Profit
Employee range
11-50 employees
Revenue range
$0-$1M
Founded
2004-01-01, Year

Headquarters

Postal code
10022
Country code
US
Continent
North America

Capital profile

Funding and company signals

Funding stage
IPO
Funding rounds
11
Total equity funding
$406M
Last funding
Post IPO Equity / $100M / 2025-11-04
Last equity funding
Post IPO Equity / $100M
Investors
10
Founders
2
Articles
145
Exited on
2014-08-06

Founders and investors

Founders

Najib BabulPaolo Manfredi, MD

Investors

Ben Franklin Technology Partners of Southeastern PennsylvaniaBioAdvanceColumbia Threadneedle InvestmentsJanus Henderson InvestorsOrbiMed